Download MendeleyAllosteric Antagonist Modulation of TRPV2 by Piperlongumine Impairs Glioblastoma Progression.
Conde, J., Pumroy, R.A., Baker, C., Rodrigues, T., Guerreiro, A., Sousa, B.B., Marques, M.C., de Almeida, B.P., Lee, S., Leites, E.P., Picard, D., Samanta, A., Vaz, S.H., Sieglitz, F., Langini, M., Remke, M., Roque, R., Weiss, T., Weller, M., Liu, Y., Han, S., Corzana, F., Morais, V.A., Faria, C.C., Carvalho, T., Filippakopoulos, P., Snijder, B., Barbosa-Morais, N.L., Moiseenkova-Bell, V.Y., Bernardes, G.J.L.(2021) ACS Cent Sci 7: 868-881
- PubMed: 34079902
- DOI: https://doi.org/10.1021/acscentsci.1c00070
- Primary Citation of Related Structures:
6WKN - PubMed Abstract:
The use of computational tools to identify biological targets of natural products with anticancer properties and unknown modes of action is gaining momentum. We employed self-organizing maps to deconvolute the phenotypic effects of piperlongumine (PL) and establish a link to modulation of the human transient receptor potential vanilloid 2 (hTRPV2) channel. The structure of the PL-bound full-length rat TRPV2 channel was determined by cryo-EM. PL binds to a transient allosteric pocket responsible for a new mode of anticancer activity against glioblastoma (GBM) in which hTRPV2 is overexpressed. Calcium imaging experiments revealed the importance of Arg539 and Thr522 residues on the antagonistic effect of PL and calcium influx modulation of the TRPV2 channel. Downregulation of hTRPV2 reduces sensitivity to PL and decreases ROS production. Analysis of GBM patient samples associates hTRPV2 overexpression with tumor grade, disease progression, and poor prognosis. Extensive tumor abrogation and long term survival was achieved in two murine models of orthotopic GBM by formulating PL in an implantable scaffold/hydrogel for sustained local therapy. Furthermore, in primary tumor samples derived from GBM patients, we observed a selective reduction of malignant cells in response to PL ex vivo . Our results establish a broadly applicable strategy, leveraging data-motivated research hypotheses for the discovery of novel means tackling cancer.
Organizational Affiliation:
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
